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of type 2 autoimmune pancreatitis.  Conclusion: This case 
highlights the challenge in the diagnostic approach of a pan-
creatic mass, particularly in distinguishing benign from ma-
lignant disease.  © 2017 Sociedade Portuguesa de Gastrenterologia
Published by S. Karger AG, Basel 
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 Resumo 
 Introdução: A pancreatite autoimune é uma entidade 
rara, de etiopatogenia desconhecida, que pode simular 
cancro do pâncreas e cujo diagnóstico envolve a integra-
ção de dados clínicos, serológicos, imagiológicos e histo-
lógicos. Descrevem-se dois tipos de pancreatite autoimu-
ne: tipo 1, cujo envolvimento pancreático integra o espe-
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 Abstract 
 Introduction: Autoimmune pancreatitis is a rare entity of un-
known etiology that can mimic pancreatic cancer and whose 
diagnosis involves clinical, serological, imagiological, and 
histological findings. There are two types of autoimmune 
pancreatitis: type 1, in which the pancreas is involved as one 
part of a systemic immunoglobulin G4-related disease, and 
type 2, generally without immunoglobulin G4-positive cells 
and without systemic involvement.  Case: We report the case 
of a 45-year-old female, who underwent an abdominal mag-
netic resonance imaging for etiological study of a solid liver 
lesion, which revealed a tail pancreatic mass. Laboratory 
analyses showed normal levels of immunoglobulin G4 and 
negative antinuclear antibodies. Endoscopic ultrasound re-
vealed a homogeneous and hypoechogenic lesion in the 
pancreatic tail with a “sausage-like” appearance. Endoscopic 
ultrasound-guided fine needle aspiration was inconclusive 
and the patient underwent a laparoscopic distal pancreatec-
tomy. Histopathology examination confirmed the diagnosis 
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tro das doenças associadas à imunoglobulina G4, e tipo 2, 
geralmente sem evidência de células imunoglobulina G4 
positivas e sem manifestações sistémicas. Caso: Apresen-
tamos o caso de uma mulher de 45 anos, submetida a res-
sonância magnética abdominal para esclarecimento etio-
lógico de lesão nodular hepática que revelou uma massa 
na cauda do pâncreas. Analiticamente apresentava imu-
noglobulina G4 normal e anticorpos antinucleares nega-
tivos. A ultrassonografia endoscópica revelou uma lesão 
homogénea e hipoecogénica na cauda pancreática com 
morfologia “em salsicha”. A punção aspirativa por agulha 
fina foi inconclusiva tendo a doente sido submetida a 
pancreatectomia distal por via laparoscópica. O exame 
histopatológico confirmou o diagnóstico de pancreatite 
autoimune tipo 2. Conclusão: Este caso destaca o desafio 
na abordagem diagnóstica da massa pancreática, particu-
larmente na diferenciação entre patologia benigna e ma-
ligna.  © 2017 Sociedade Portuguesa de Gastrenterologia
Publicado por S. Karger AG, Basel
 Introduction 
 Autoimmune pancreatitis (AIP) is a fibro-inflamma-
tory disease that accounts for 4.6–5% of chronic pancre-
atitis and comprises two entities, currently designated as 
type 1 and type 2, which have unique histopathological 
patterns and differ significantly in their demographic 
profiles, clinical presentation, and natural history  [1, 2] . 
Type 1 has been recognized as the pancreatic manifesta-
tion of a multiorgan disease, named immunoglobulin G4 
(IgG4)-related disease, while type 2 is a pancreatic spe-
cific disorder not associated with IgG4.
 The diagnostic criteria for AIP are a combination of 
imagiological, laboratorial, and histopathological find-
ings. International criteria for the diagnosis of AIP have 
been defined, such as the HISORt (histology, imaging, 
elevated serum IgG4 levels, other organ involvement, and 
response to steroids) criteria  [3] from the Mayo Clinic 
and, most recently, International Consensus Diagnostic 
Criteria from International Association of Pancreatology 
 [4] . Despite this, the definitive diagnosis of AIP, particu-
larly type 2, is challenging, as this disorder commonly 
presents as a pancreatic mass mimicking pancreatic can-
cer. Misdiagnosis has the potential to be catastrophic as 
an undiagnosed cancer may cause delay or loss of the op-
portunity for potential curative surgery. The opposite 
scenario of a pancreatic surgery performed for benign 
disease, with its high risk of morbidity and mortality, is 
also unsatisfactory.
 Herein, we report an uncommon case of type 2 AIP 
presented as a pancreatic mass illustrating the challenge 
in the differential diagnosis between AIP and pancreatic 
cancer.
 Case Report 
 A 45-year-old Caucasian female underwent an abdominal 
magnetic resonance imaging (MRI) for etiological study of a solid 
liver lesion (focal nodular hyperplasia), detected on routine ab-
dominal ultrasound, which revealed a tail pancreatic solid lesion 
of undetermined etiology. She had a medical history of arterial 
hypertension and ulcerative colitis treated with bisoprolol and me-
salazine. She reported no history of smoking or alcohol consump-
tion. There was no evidence of fever, jaundice, abdominal pain, 
anorexia, weight loss, or other gastrointestinal symptoms. Physical 
examination was unremarkable. Laboratory analysis revealed no 
anemia and liver tests, amylase, lipase, C reactive-protein, eryth-
rocyte sedimentation rate, CA 19-9, and IgG4 were normal. Anti-
nuclear antibodies were negative. In order to clarify the nature of 
the referred lesion, an endoscopic ultrasound (EUS) was per-
formed, which revealed a homogeneous and hypoechogenic le-
sion, with 40 mm of greater diameter, in the pancreatic tail with a 
“sausage-like” appearance ( Fig. 1 a). This lesion showed no vascu-
lar pattern on Doppler examination ( Fig. 1 b). There were no pan-
creatic calcifications and common biliary duct, pancreatic duct, 
and splenoportal axis were normal. An EUS-guided fine needle 
aspiration (FNA) with a 19-gauge needle was performed ( Fig. 1 c), 
whose cytological analysis showed abundant inflammatory infil-
trate and ductal epithelium with mild to moderate atypia, appar-
ently reactive ( Fig. 1 d). Given that the pancreatic adenocarcinoma 
hypothesis could not be excluded, the patient underwent a laparo-
scopic distal pancreatectomy. Histopathology examination con-
firmed the diagnosis of a type 2 autoimmune pancreatitis ( Fig. 2 ). 
At the 6-month follow-up, the patient remained asymptomatic 
with no evidence of recurrence.
 Discussion 
 A rare form of idiopathic chronic pancreatitis was first 
described in 1961 by Sarles et al.  [5] . The term “autoim-
mune pancreatitis” was introduced by Yoshida et al.  [6] 
in 1995 to describe a steroid-responsive disease associat-
ed with autoimmune features. In 2009, two subtypes of 
AIP, called type 1 (lymphoplasmacytic sclerosing pancre-
atitis) and type 2 (idiopathic duct-centric pancreatitis), 
were formally recognized  [1, 2] .
 AIP is a rare disorder, with a reported prevalence in 
Japan of 0.82/100,000. Concerning subtypes, type 1 is the 
most prevalent worldwide while type 2 is more common 
in Europe and North America. In an international study 
of 1,064 patients, the average age at the time of diagnosis 
was 61.4 and 39.9 years for types 1 and 2, respectively, 
 Martins/Lago/Sousa/Araújo/Davide/
Castro-Poças/Pedroto
 
GE Port J Gastroenterol 2017;24:296–300
DOI: 10.1159/000461589
298
a b
c d
 Fig. 1. Endosonographic and cytological 
findings. Endoscopic ultrasound revealed a 
homogeneous and hypoechoic lesion with 
a “sausage-like” appearance in the pancre-
atic tail ( a ) with no vascular pattern on 
Doppler examination ( b ). Endoscopic ul-
trasound-guided fine needle aspiration ( c ). 
Clusters of ductal cells with moderate atyp-
ia on cytology ( d ) (H&E; ×200). 
a b
c d
 Fig. 2. Histopathological features.
 a–c Dense lymphoplasmocytic and granu-
locytic infiltration within epithelium and 
lumen ducts (granulocytic epithelial le-
sion), obliterative phlebitis, fibrosis, and 
acinar atrophy (H&E;  a ×20;  b ×40;  c ×200). 
 d Rare immunoglobulin G4-positive cells 
on immunohistochemistry (IHC; ×40). 
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with a proportion of male patients significantly higher in 
type 1 (77 vs. 55%)  [7] .
 The clinical picture of AIP depends on its subtype. 
Type 1 is more prevalent among older males and be-
longs to the IgG4-related systemic disease, which is as-
sociated with high serum and/or tissue IgG4 and other 
autoimmune disorders, including IgG4 cholangitis, 
sclerosing sialadenitis, interstitial nephritis, and retro-
peritoneal fibrosis. The classic clinical presentation in 
type 1 is painless obstructive jaundice (up to 75% of cas-
es) mimicking pancreatic cancer. Other clinical features 
include chronic or recurrent abdominal pain (68%), 
acute pancreatitis, and steatorrhea. On the other hand, 
type 2 AIP affects mainly younger patients, without a 
gender predilection, and often is not associated with hy-
per-IgG4. As in type 1, type 2 also frequently presents 
with obstructive jaundice (50% of cases) but without 
systemic involvement, except for inflammatory bowel 
disease which is present in about 30% of cases, particu-
larly ulcerative colitis  [8] .
 Overall, the pancreatic disease in patients with AIP can 
present in different ways including (1) a focal mass or dif-
fuse enlargement on imaging that can be confused with 
pancreatic cancer (85% of cases), (2) mild abdominal pain 
with or without acute or chronic pancreatitis, (3) stric-
tures of the pancreatic duct, and (4) peripancreatic vascu-
lar complications (23%)  [9] . We report a case of a solid 
pancreatic mass incidentally detected on abdominal MRI 
in an asymptomatic young female patient with history of 
ulcerative colitis.
 Diagnosis of AIP is challenging, particularly in type 2. 
Correct diagnosis can help avert the consequences of pro-
gressive disease and unnecessary surgery. In the last de-
cade, several diagnostic criteria were proposed including 
clinical, serological, imagiological, and histological find-
ings. In order to unify the heterogeneity of diagnostic cri-
teria, a multinational group convened in 2011 and devel-
oped International Consensus Diagnostic Criteria for 
AIP  [4] .
 Due to its ability to provide high-resolution imaging, 
EUS emerged as an important diagnostic tool. Most 
common endosonographic findings are focal or diffuse 
“sausage-shaped” pancreatic enlargement, homoge-
neous echo pattern, stranding, and calcifications. A long 
and/or multiple strictures of the pancreatic duct, without 
significant associated dilation, is also highly characteris-
tic of AIP. The other advantage of EUS is the possibility 
to perform FNA or core biopsy, which provides tissue 
samples for cytological or histological diagnosis. Despite 
the poor sensitivity (up to 37.5%) and specificity of EUS-
guided FNA, the recent advent of spring-loaded biopsy 
needles provides a high diagnostic accuracy (about 85%) 
 [10, 11] . Elastography and contrast-enhanced EUS are 
newer noninvasive technologies that may help differenti-
ate benign from malignant solid pancreatic lesions. Al-
though both of these techniques may increase the diag-
nostic yield of EUS, there are a considerable number of 
issues that remain to be solved, requiring additional 
studies.
 The definitive diagnosis of type 2 AIP always requires 
histology, revealing an idiopathic duct-centric pancreati-
tis, the hallmarks of which are granulocytic epithelial le-
sions. IgG4 plasma cells are absent or in small number. 
Obliterative phlebitis and fibrosis are less prominent than 
in type 1  [1, 2] .
 Unlike other forms of pancreatitis, AIP is highly re-
sponsive to steroid therapy  [13] . The diagnosis of AIP 
should be reconsidered in patients who do not respond to 
steroids. The relapse rate in patients with type 1 AIP rang-
es from 30–60%, while patients with type 2 typically do 
not relapse (<5%)  [14] . Immunosuppressors, such as aza-
thioprine or mycophenolate mofetil, are used in patients 
with relapse or steroid-resistant disease. Spontaneous re-
mission is seen in 24–55% of patients  [12, 13] . In spite of 
this, early steroid therapy is recommended because, if un-
treated, the pancreatic and biliary disease can progress to 
irreversible pancreatic insufficiency and secondary bili-
ary cirrhosis.
 In this case, the patient underwent EUS and the ultra-
sonographic features were suggestive of AIP. Although 
the clinical, laboratory, and imaging findings favor the 
diagnosis of autoimmune pancreatitis, the hypothesis of 
pancreatic cancer could not be completely excluded due 
to the presence of moderate ductal atypia on cytology. 
Therefore, the case was discussed at a multidisciplinary 
meeting, and, in order to definitively rule out a more om-
inous lesion, a surgical approach was decided, allowing a 
definitive diagnosis.
 In conclusion, this report describes an uncommon en-
tity highlighting the challenge in the diagnostic approach 
of a pancreatic mass. Although the diffuse form of AIP 
can be easily distinguished from pancreatic cancer on im-
aging, differentiating focal AIP from pancreatic malig-
nancy is challenging, like in the presented case. Making 
the correct diagnosis and differentiating AIP from pan-
creatic cancer is of the utmost importance; an agreed di-
agnostic pathway should be in place and a multidisci-
plinary approach taken with each patient.
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